Single Point Partners’s Haemonetics HAE Stock Holding History

Single Point Partners’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-14,368	Closed	-$1.19M	–	95
2023 Q1	$1.19M	Hold	14,368	–	–	0.26%	41
2022 Q4	$1.13M	Hold	14,368	–	–	0.27%	41
2022 Q3	$1.06M	Hold	14,368	–	–	0.29%	40
2022 Q2	$937K	Buy	+14,368	New	+$850K	0.26%	37

Other funds holding HAE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Single Point Partners's HAE Position: Q2 2023 in Review

Single Point Partners sold out of Haemonetics (HAE) in Q2 2023, closing a stake of 14,368 shares — an estimated $1.19M sold.

Single Point Partners first reported a position in HAE in Q2 2022 and held it in 4 quarters. The position peaked at $1.19M in Q1 2023. 296 funds tracked by Wall St. Rank hold HAE as of Q2 2023.

Single Point Partners reported no remaining Haemonetics position as of Q2 2023 after selling out during the quarter.
Single Point Partners sold 14,368 Haemonetics shares in Q2 2023, an estimated $1.19M.
Single Point Partners first reported a position in Haemonetics in Q2 2022 and held it in 4 quarters.
Single Point Partners's Haemonetics position peaked at $1.19M in Q1 2023.
296 funds tracked by Wall St. Rank held Haemonetics as of Q2 2023.

Based on Single Point Partners's 13F filing for Q2 2023, filed 10 Jul 2023.